ArticleEuropean journal of nuclear medicine and molecular imaging2026
Head-to-Head comparison of [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveA prospective comparison was conducted between [¹⁸F]AlF-NOTA-TATE and the routinely used clinical imaging agent [⁶⁸Ga]Ga-DOTA-TATE in patients with neuroendocrine tumors (NETs) to evaluate diagnostic performance, pharmacokinetic characteristics, and safety. Additionally, the clinical potential of [¹⁸F]AlF-NOTA-TATE as an alternative imaging agent was explored.
methods[¹⁸F]AlF-NOTA-TATE was synthesized automatically using a self-developed direct purification technology based on column chromatography, with strict adherence to quality control standards. A clinical comparative study enrolled 20 patients with suspected or confirmed neuroendocrine tumors (NETs) (median age: 52 years). All patients underwent PET/CT imaging with both [¹⁸F]AlF-NOTA-TATE (7.8 ± 1.8 mCi) and [⁶⁸Ga]Ga-DOTA-TATE (3.9 ± 0.6 mCi) within a 3-day interval. Image analysis included evaluation of parameters such as lesion detection rate, maximum standardized uptake value (SUVmax), and tumor-to-background ratio (TBR). In parallel, radiation dosimetry and biodistribution characteristics were also assessed.
resultsAmong the 20 patients, 13 were diagnosed with NETs, 4 exhibited negative imaging findings, and 3 had non-NET lesions. Biodistribution analysis revealed that [¹⁸F]AlF-NOTA-TATE showed higher physiological uptake in normal organs such as the pituitary gland and spleen compared to [⁶⁸Ga]Ga-DOTA-TATE, but lower uptake in the brain and blood pool. The overall lesion detection rates of [¹⁸F]AlF-NOTA-TATE and [
conclusion[¹⁸F]AlF-NOTA-TATE demonstrated a comparable lesion detection rate to [⁶⁸Ga]Ga-DOTA-TATE for the diagnosis of neuroendocrine tumors (NETs), while exhibiting higher tumor uptake and superior tumor-to-background ratios (TBR). These results suggest that [¹⁸F]AlF-NOTA-TATE may serve as a promising alternative for the diagnosis of NETs.
trial registrationChinese Clinical Trial Registry (ChiCTR2300072266), registered on 8 June 2023.
Indexed as
Identifiers
40938396What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.